2023 brought several changes to the R&D tax credit and its related provisions. As many of you already know, the R&D tax credit can be used to offset both INCOME taxes and/or PAYROLL taxes depending on your company’s eligibility status. Let’s start with the change that would be relevant to your entity’s income taxes. Some are very business friendly while others are not. Here is a list of what you need to know for your business entity taxes and for your personal taxes starting in 2023.

1. Section 174 – Amortization of R&D Expenses

Back in 2017, when Congress enacted several rule changes on business taxes, this sleeper rule was put in place to be effective for tax years starting in 2022. For the tax year starting in 2022, all of the R&D expenses (not credits) need to be capitalized and deducted through a 5-year or 15-year amortization schedule depending on if they are domestic or foreign R&D. This requirement is hurting businesses with cash flow constraints that are otherwise able to deduct the R&D expenses outright before 2022.

For example, your business had 100 dollars of revenue, and you spent 100 dollars on doing qualified research work including paying your employees. Before 2022, you would end up with ZERO taxable income (100 -100 = 0). With this new rule, however, your taxable income is going to be $90 dollars (100 – 10 =90), and with a tax rate of 21%, you will now need to pay $18.9 tax to the IRS. So what happened with the math here? Well, only the $10 from the $100 R&D expenses is allowed as a deduction this year, and the rest are deductible in future years. Although you will get an extra deduction next year, this is creating an artificial income with real tax liabilities for businesses. Even if you claim R&D Credits on the $90 dollars, you are still left with a tax bill at the end.

At the time of this writing, there are no signs of this tax provision getting repealed by Congress although there have been several attempts made by both sides of the House representatives to eliminate it. So how businesses are dealing with it currently? In short, the word has been “waiting”. But others have taken different approaches:

It is important to know that for companies that are pre-revenue, have prior NOL, or still be in the loss even with the amortization, Section 174 doesn’t make any cash flow impact, and businesses are claiming R&D expenses and credits as usual.

2. Increase in Payroll Credits Offset Starting Q1 2023

Starting in 2023, The Inflation Reduction Act of 2022 (IRA) allowed credits claimed in the past to offset both the employer portion of the Social Security Tax (6.2% of wage) and Medicare Tax (1.45% of wage). This allows companies to offset more expenses (Medicare Taxes) although the 1.45% more refund on wages in 2023 won’t make it a huge saving for any businesses.

This added benefit will likely speed up the existing credit utilization, which would suggest that Companies should file 2022 returns sooner to have fresh R&D credits ready to go. Again, the payroll credit utilization rule is that the Company can only start the credit offset in the quarter after the return was filed.

3. Increase the R&D Credits Election Amount to $500,000

The same IRA states that for tax years starting after 12/31/2022, up to $500,000 of credits can be elected on a timely filed return (including extension). The payroll tax credit is first used to reduce the employer’s share of social security tax up to $250,000 per quarter and any remaining credit reduces the employer’s share of Medicare tax for the quarter. Any remaining credit, after reducing the employer share of social security tax and the employer share of Medicare tax, is then carried forward to the next quarter.

This is definitely good news for most businesses that perform qualified research and development activities.

If you have any questions regarding how to claim, how to use, or need help with your R&D credits. Please submit an inquiry or book a free consultation with Zhen.

Leave a Reply

Your email address will not be published. Required fields are marked *